Selective Imbalances of Cellular Immune Responses by Adriamycin

  • M. J. Ehrke
  • K. Ryoyama
  • V. Tomazic
  • S. A. Cohen
  • E. Mihich
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 75)


It has been demonstrated that spleen cells from mice treated with adriamycin not only develop an increased cell-mediated immune response during culture with allogeneic tumor cells, but also have increased phagocytic activity following culture, respond to heat-treated (45° C) alloantigen, develop an increased suppressor cell function, and are less sensitive to a suppressor cell activity. Thus, changes in spleen cell subpopulations occuring in the donor mice consequent to drug treatment result in demonstrable selective imbalances of cellular functions involved in the immune response. One cell type which has been implicated as being necessary in the expression of all these functions is the monocyte-macrophage, and it is suggested that an effect of adriamycin on progenitors of this cell type may lead to the imbalances.


Spleen Cell Suppressor Cell Suppressor Cell Activity Allogeneic Tumor Cell Suppressor Cell Function 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cohen SA, Ryoyama K, Ehrke MJ, Mihich E (1979) Characterization of the cytotoxic effector cells (CTE) generated in the augmented in vitro primary immune response of spleen cells from mice pretreated with adriamycin (AM). Proc Am Assoc Cancer Res 20:181Google Scholar
  2. 2.
    Ehrke MJ, Cohen SA, Mihich E (1978) Selectivity of inhibition by anticancer agents of mouse spleen immune effector functions involved in responses to sheep erythrocytes. Cancer Res 38:521PubMedGoogle Scholar
  3. 3.
    Ehrke J, Tomazic V, Eppolito C, Mihich E (1978) Effects of adriamycin (AM) in mice or in culture on the primary immune response of C57BL/6 spleen cells to allogeneic P815 mastocytoma cells. Fed Proc 37:1652Google Scholar
  4. 4.
    Hersh EM (1974) Immunosuppressive agents. In: Sartorelli AC, Johns DG (eds) Antineoplastic and immunosuppressive agents I. Springer, New York, pp 577–617Google Scholar
  5. 5.
    Mihich E (1977) Chemotherapy and immunotherapy as a combined modality of cancer treatment. Proceedings 7th international symposium on the biological characterization of human tumours, Budapest, April 13–15. Excerpta Medica, Amsterdam. ISBN 0 444 90014 4, pp 113–121Google Scholar
  6. 6.
    Mihich E (1979) Drug selectivity in the suppression of the immune response. In: Turk JL (ed) Drugs and immune responsiveness. Macimillan, London, pp 25–39Google Scholar
  7. 7.
    Mihich E (1971) Preclinical evaluation of the interrelationships between cancer chemotherapy and immunity. In: Hall TC (ed) Prediction of response in cancer therapy. US Government Printing Office, NCI Monograph 34, pp 90–116Google Scholar
  8. 8.
    Mantovani A (1977) In vitro and in vivo cytotoxicity of adriamycin and daunomycin for murine macrophages. Cancer Res 37:815–820PubMedGoogle Scholar
  9. 9.
    Mantovani A, Vecchi A, Tagliabue A, Spreafico F (1976). The effects of adriamycin and daunomycin on antitumoral immune effects on mechanisms in an allogeneic system. Eur J Cancer 12:371–377PubMedCrossRefGoogle Scholar
  10. 10.
    Orsini F, Pavelic Z, Mihich E (1977) Increased primary cell-mediated immunity in culture subsequent to adriamycin or daunorubicin treatment of spleen donor mice. Cancer Res 37:1719–1726PubMedGoogle Scholar
  11. 11.
    Schwartz HS, Grindey GB (1973) Adriamycin and daunorubicin: A comparison of antitumor activities and tissue uptake in mice following immunosuppression. Cancer Res 33:1837–1844PubMedGoogle Scholar
  12. 12.
    Schenel DJ, Bach FH (1974) Genetic control of cell-mediated lympholysis in mouse. J Exp Med 140:1534–1539CrossRefGoogle Scholar
  13. 13.
    Tomazic V, Ehrke MJ, Mihich E (1979) Studies on the cellular basis for the augmentation by adriamycin (AM) of the response of mouse spleen cells to allogeneic tumor in culture. Fed Proc 38:1214Google Scholar
  14. 14.
    Vecchi A, Mantovani A, Tagliabue A, Spreafico F (1976) A characterization of the immunosuppressive activity of adriamycin and daunomycin on humoral antibody production and tumor allograft rejection. Cancer Res 36:1222–1227PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1980

Authors and Affiliations

  • M. J. Ehrke
  • K. Ryoyama
  • V. Tomazic
  • S. A. Cohen
  • E. Mihich

There are no affiliations available

Personalised recommendations